Article

Bbarrons.com on 2022-01-22 01:14

Biogen After the Alzheimer’s Drug Debacle: Time to Sell the Parts? 4 min read

The Centers for Medicare and Medicaid may ensure the commercial death of Biogen’s controversial Alzheimer’s drug. And that leads at least one analyst ...

Related news

BBiogen After the Alzheimer’s Drug Debacle: Time to Sell the Parts? 4 min read barrons.com
BWhy Biogen Could Need to Sell 'for Parts'3 min read barrons.com
Wall Street
BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min read barrons.com
BLilly Joins Biogen as Alzheimer’s Drugs Finally Emerge 3 min read barrons.com
Japan
BBiogen and Eisai Strengthen Lead in Alzheimer’s Drug Race. The Stocks Are Rising. 2 min read barrons.com
FBiogen predicts preventive Alzheimer’s drug ft.com
South East Asia , China
FFDA approves Biogen Alzheimer’s drug ft.com
BBiogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy.2 min read barrons.com
Stock Island , Mizuho-machi
MAlzheimer’s expert says more clinical trials are needed for controversial Biogen drug marketwatch.com
New York , San Diego , Japan
Panels find FDA, Biogen rushed Alzheimer’s drug Arkansas Online
Philadelphia , Cambridge
FBiogen to seek Alzheimer’s drug approval ft.com
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm The New York Times
Biogen Alzheimer’s Drug Impresses in Early Study wsj.com
BBiogen’s Alzheimer’s Drug Has Another Shot at Success3 min read barrons.com
Wall Street
Biogen stock surges despite skepticism over Alzheimer’s drug plan bizjournals.com
Biogen CEO: ‘Major bottleneck’ still limits Alzheimer’s drug Seattle Times
Massachusetts , Cambridge